摘要
目的探讨厄贝沙坦联合瑞舒伐他汀对合并心血管疾病的早期糖尿病肾病(DN)的治疗效果及对基质细胞衍生因子1/趋化因子受体4(SDF-1/CXCR4)表达的影响。方法选取2016年1月至2017年12月临海市第二人民医院收治的的合并心血管疾病的早期DN患者130例为研究对象,采用随机数字表法分为三组,即厄贝沙坦组(对照1组,n=43)、瑞舒伐他汀组(对照2组,n=43)和厄贝沙坦联合瑞舒伐他汀组(观察组,n=44),比较三组临床疗效,血压、血脂水平及SDF-1/CXCR4表达。结果治疗后,观察组总有效率为93.18%(41/44),对照1组总有效率为69.77%(30/43),对照2组总有效率为74.42%(32/43),三组差异均有统计学意义(χ2=12.341、10.106,均P<0.05)。治疗后,观察组收缩压(SBP)、舒张压(DBP)水平与对照1组、对照2组比较,差异均有统计学意义(F=23.087、20.249,均P<0.05)。治疗后,观察组胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)与对照1组、对照2组比较,差异均有统计学意义(F=18.408、15.623、14.852、9.845,均P<0.05)。治疗后,观察组SDF-1水平较治疗前显著提高且与对照1组、对照2组比较,差异有统计学意义(F=21.085,P<0.05)。治疗后,观察组CXCR4阳性率较治疗前显著提高,且与对照1组、对照2组比较,差异有统计学意义(F=23.641,P<0.05)。结论厄贝沙坦联合瑞舒伐他汀对合并心血管疾病的早期DN的临床疗效显著,可有效改善患者血压、血脂水平,显著提高SDF-1水平及CXCR4阳性率。
Objective To investigate the effect of irbesartan combined with resuvastatin on early diabetic nephropathy(DN) complicated with cardiovascular disease,and its influence on SDF-1/CXCR4 expression. Methods From January 2016 to December 2017,130 early DN patients complicated with cardiovascular disease in the Second People's Hospital of Linhai were selected as study objects,and according to the digital table,they were randomly divided into three groups: irbesartan group(control group 1,n=43),resuvastatin group(control group 2,n=43) and irbesartan combined with resuvastatin group(observation group,n=44).The clinical efficacy,blood pressure,blood lipids and SDF-1/CXCR4 expression were compared among the three groups. Results After treatment,the total effective rate in the observation group was 93.18%(41/44),which in the control group 1 was 69.77%(30/43),which in the control group 2 was 74.42%(32/43),there was statistically significant difference among the three groups(χ2=12.341,10.106,all P<0.05).After treatment,the levels of SBP and DBP in the observation group had statistically significant differences compared with those in the control group 1 and control group 2(F=23.087,20.249,all P<0.05).After treatment,there were statistically significant differences in TC,TG,HDL-C and LDL-C between the observation group and control group 1,control group 2(F=18.408,15.623,14.852,9.845,all P<0.05).After treatment,the level of SDF-1 in the observation group was significantly higher than that before treatment,and which was also significantly higher than that in the control group 1 and control group 2(F=21.085,P<0.05).After treatment,the positive rate of CXCR4 in the observation group was significantly higher than that before treatment,and compared with that in the control group 1 and control group 2,the difference was statistically significant(F=23.641,P<0.05). Conclusion Irbesartan combined with resuvastatin in the treatment of early DN patients with cardiovascular disease has significant clinical efficacy,can effectively improve blood pressure and blood lipid levels,significantly improve the level of SDF-1 and CXCR4 positive rate.
作者
汤春光
王利宏
Tang Chunguang;Wang Lihong(Department of Cardiovascular Internal Medicine,the Second People's Hospital of Linhai,Taizhou,Zhejiang 317016,China;Department of Cardiovascular Internal Medicine,People's Hospital of Zhejiang Province,Hangzhou,Zhejiang 310014,China)
出处
《中国基层医药》
CAS
2018年第24期3162-3165,共4页
Chinese Journal of Primary Medicine and Pharmacy
关键词
糖尿病肾病
心血管疾病
血压
血脂
基质细胞衍生因子1
受体
趋化因子
Diabetic nephropathy
Cardiovascular diseases
Blood pressure
Blood fat
Stromal cell-derived factor1
Receptors,chemokine
